Brant Binder


Brant is a co-founder and currently President of ZebiAI Therapeutics, Inc.  He also co-founded Psy Therapeutics and X-Body Biosciences, which was sold to JUNO Therapeutics in 2015.  In addition, Brant is a past co-founder and BOD member of X-Chem Pharmaceuticals.

Prior to his involvement in the commercialization of DNA-encoded library platform companies, Brant was a founder and CEO of optical instrument company, SRU Biosystems.  Brant began his career in venture capital and private equity investment at Trust Company of the West.  He is a graduate of MIT’s Sloan School of Management (where he was a seed investor in and of Georgetown University’s School of Foreign Service.

Other Team Members

Rafael Gomez-Bombarelli, Ph.D.

Chief Learning Officer

Brant Binder


Brian Goldman, Ph.D.

SVP and Chief Computation Scientist

Richard Wagner, Ph.D.

Founder and Director

Ed Koval

Chief Business Officer

John Cuozzo Ph.D

SVP and Head of Drug Discovery

Christelle Huguet, Ph.D.

Chair, Scientific Advisory Board